CA2537669A1 - Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer - Google Patents

Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer Download PDF

Info

Publication number
CA2537669A1
CA2537669A1 CA002537669A CA2537669A CA2537669A1 CA 2537669 A1 CA2537669 A1 CA 2537669A1 CA 002537669 A CA002537669 A CA 002537669A CA 2537669 A CA2537669 A CA 2537669A CA 2537669 A1 CA2537669 A1 CA 2537669A1
Authority
CA
Canada
Prior art keywords
hydroxy
methyl
halogen
deazaadenin
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002537669A
Other languages
English (en)
Other versions
CA2537669C (fr
Inventor
Vern L. Schramm
Chandan Guha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2537669A priority Critical patent/CA2537669C/fr
Publication of CA2537669A1 publication Critical patent/CA2537669A1/fr
Application granted granted Critical
Publication of CA2537669C publication Critical patent/CA2537669C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2537669A 2006-02-24 2006-02-24 Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer Expired - Fee Related CA2537669C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2537669A CA2537669C (fr) 2006-02-24 2006-02-24 Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2537669A CA2537669C (fr) 2006-02-24 2006-02-24 Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer

Publications (2)

Publication Number Publication Date
CA2537669A1 true CA2537669A1 (fr) 2007-08-24
CA2537669C CA2537669C (fr) 2015-08-11

Family

ID=38433809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2537669A Expired - Fee Related CA2537669C (fr) 2006-02-24 2006-02-24 Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer

Country Status (1)

Country Link
CA (1) CA2537669C (fr)

Also Published As

Publication number Publication date
CA2537669C (fr) 2015-08-11

Similar Documents

Publication Publication Date Title
US8916571B2 (en) Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase
US20110092521A1 (en) Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases
ES2361566T3 (es) Uso de inhibidores de parp-1.
AU2010276160A1 (en) Treatment of liver disorders with PI3K inhibitors
NZ583824A (en) Azacytidine analogues and uses thereof
TW200843778A (en) Pterin analogs
JP5890043B2 (ja) 抗癌活性を有する２−デオキシ単糖の新規なアセテート
US20070161665A1 (en) Cancer treatment method
RU2445960C2 (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
Ikeda et al. Cyclic AMP augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes
CN102083829A (zh) 改良的Raf抑制剂
CA2537669C (fr) Inhibiteurs des nucleosides phosphorylases et nucleosidases pour traiter le cancer
AU2006200809B2 (en) Methods of treating cancer
KR20230136627A (ko) 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도
WO2020218562A1 (fr) Composition pharmaceutique de prévention ou de traitement d'un cancer résistant au traitement
WO2019146129A1 (fr) Composition pharmaceutique contre une tumeur présentant une mutation de l'isocitrate déshydrogénase, agent antitumoral et utilisation associée
AU2009219464A1 (en) Combination anti-cancer agents
WO2021125313A1 (fr) Agent thérapeutique contenant un composé de pyrimidine en tant que principe actif
EP0505640B2 (fr) Méthode thérapeutique améliorée
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
JP2006298892A (ja) 抗癌剤
WO2021188855A1 (fr) Promédicaments symbiotiques pour le traitement du cancer et d'autres maladies
CA3209477A1 (fr) Composition et methodes de traitement du cancer
US20060079463A1 (en) Anticancer compositions comprising methenamine
JP2001335486A (ja) プテリン誘導体含有アポトーシス抑制剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200224